NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo
Kenji Namoto,Clara Baader,Vanessa Orsini,Alexandro Landshammer,Eva Breuer,Kieu Trinh Dinh,Rosemarie Ungricht,Monika Pikiolek,Stephane Laurent,Bo Lu,Alexandra Aebi,Katharina Schönberger,Eric Vangrevelinghe,Olivera Evrova,Tianliang Sun,Stefano Annunziato,Julie Lachal,Emily Redmond,Louis Wang,Kristie Wetzel,Paola Capodieci,Jonathan Turner,Gabi Schutzius,Vincent Unterreiner,Markus Trunzer,Nicole Buschmann,Dirk Behnke,Rainer Machauer,Clemens Scheufler,Christian N. Parker,Magali Ferro,Armelle Grevot,Armin Beyerbach,Wei-Yu Lu,Stuart J. Forbes,Jürgen Wagner,Tewis Bouwmeester,Jun Liu,Bindi Sohal,Sukhdeep Sahambi,Linda E. Greenbaum,Felix Lohmann,Philipp Hoppe,Feng Cong,Andreas W. Sailer,Heinz Ruffner,Ralf Glatthar,Bostjan Humar,Pierre-Alain Clavien,Michael T. Dill,Elizabeth George,Jürgen Maibaum,Prisca Liberali,Jan S. Tchorz
DOI: https://doi.org/10.1016/j.stem.2024.03.003
IF: 23.9
2024-04-05
Cell Stem Cell
Abstract:Namoto and colleagues identify and characterize the selective small-molecule LATS kinase inhibitor NIBR-LTSi. It promotes proliferation, maintains stemness, and blocks differentiation in vitro and in vivo. NIBR-LTSi accelerates liver regeneration in mice, but systemic adverse effects associated with prolonged LATS inhibition limit its potential therapeutic benefits.
cell biology,cell & tissue engineering